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165. Relapsing fever borreliosis
Sally Cutler
HISTORY
The relapsing fever spirochetes comprise a
number of different species (Table 165.1) with
many transmitted by specific tick species.
Borrelia recurrentis is the notable exception in that
it is transmitted by clothing lice.
CLINICAL PRESENTATION
The chief sign is that of fever, often accompanied
by chills, headaches, arthralgia, myalgia, and
tachycardia. Other signs may include jaundice,
petecheal rash, conjunctivitis, nausea, hepatosple-
nomegaly, and epistaxis. Infection with Borrelia
Table 165.1 Characteristics of relapsing fever borrelliae
Organism name Arthropod vector/reservoir
Vertebrate
reservoirs Clinical infection Geographic region
B. recurrentis Pediculus humanus humanus Man LBRF – human Africa (formerly worldwide)
B. baltazardii Unknown Unknown TBRF – human Iran
B. crocidurae Ornithodoros sonrai Rodents TBRF – human West Africa
B. duttonii Ornithodoros moubata Man TBRF – human Africa (Central, Eastern)
B. hermsii Ornithodoros hermsi Rodents TBRF – human;
canine
Canada, Western USA
B. hispanica Ornithodoros marocanus; Ornithodoros occidentalis;
Ornithodoros kairouanensis
(formerly Ornithodoros erraticusa)
Rodents TBRF – human Algeria, Morocco, Portugal,
Spain, Tunisia
B. latyschewii Ornithodoros tartakovskyi Rodents;
reptiles
TBRF – human Central Asia, Iran, Iraq
B. mazzottii Ornithodoros talaje Armadillos;
rodents
TBRF – human Southern USA, Mexico,
Guatemala
B. merionesi Ornithodoros costalis
Ornithodoros merionesi
Rodents Unknown North Africa
B. microti Ornithodoros erraticusb Africa, Iran
B. parkeri Ornithodoros parkeri Rodents TBRF – human Western USA
B. persica Ornithodoros tholozani Rodents; bats TBRF – human; cat Asia, Middle East
B. turicatae Ornithodoros turicata Rodents TBRF – human;
canine; birds
USA, Mexico
B. venezuelensis Ornithodoros rudis Rodents TBRF – human Central and South America
a Ornithodoros erraticus represented a complex. Recent taxonomic molecular studies redressed the phylogeny suggesting that O. erraticus sensu stricto
not an efficient vector for Borrelia.
b Molecular confirmation of O. erraticus identity unavailable at time of writing.
Abbreviations: LBRF ¼ louse-borne relapsing fever; TBRF ¼ tick-borne relapsing fever.
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duttonii has been associated with significant peri-
natal mortality in endemic regions such as
Tanzania.
Although eventually eliminated by the adap-
tive immune response, repeat infections can occur
in a previously infected individual.
TREATMENT (TABLE 165.2)
Cases are usually managed with penicillin,
doxycycline, or tetracycline treatment. Some
prefer penicillin as it is believed that this makes
Jarisch–Herxheimer reactions (JHR) less likely.
Less frequently, cephalosporins, erythromycin,
and chloramphenicol have been used.
JHR
The JHR was first described by Adolf Jarisch in
1895 and later by Karl Herxheimer in 1902, in
relation to another spirochetal infection, syphilis,
but this also occurs in approximately 5% of
relapsing fever patients upon treatment. Patients
may show an exacerbation of symptoms or
“therapeutic shock” during the initial 24 hours
post commencing treatment. The JHR is mediated
by a release of pyrogenic cytokines (including
tumor necrosis factor-α [TNF-α], interleukin
[IL]-6, and IL-8) and is treated symptomatically.
TRANSMISSION AND PATHOGENESIS
Transmission of tick-borne relapsing fever (TBRF)
occurs during the feeding of Ornithodoros soft
ticks (up to 20–30 minutes), generally whilst their
host is sleeping. The spirochetes may be present
within the tick salivary glands, coxal fluid, and
feces, facilitating transmission to their vertebrate
host. Transovarial transmission occurs for some
TBRF borreliae.
Unlike TBRF, in louse-borne relapsing fever
(LBRF) the borreliae within the louse vector pene-
trate the louse’s gut epithelium where they can
multiply in the louse hemolymph and are also
able to be excreted in louse feces, but do not
undergo transovarial transmission. Human trans-
mission occurs through crushing lice or their
feces into skin abrasions often through scratching.
Once the human is infected, spirochetes multi-
ply in the blood, sometimes to levels of up to
100 000/mm3. This spirochetemia evokes the typ-
ical febrile response after which this infection is
named. The induced antibody response clears the
bloodborne infection; however, the spirochtes
soon re-emerge having undergone antigenic vari-
ation. A new wave of infection follows that again
is eventually controlled through the host’s anti-
body response. Clinically, up to 4 to 5 febrile
episodes can occur in LBRF, whilst up to
13 relapses have been recorded for TBRF. Persist-
ence within the human host is a result of a com-
plex interplay of antigenic variation, complement
evasion strategies, erythrocyte rosetting, and
potentially other mechanisms.
The spirochetes show varying neurotropic
potential. This can promote cerebral hemorrhage,
for example with B. recurrentis. They cross the
placenta with associated foetal loss through
abortion or congenital infection, particularly
B. duttonii. Myocarditis and hepatic failure may
complicate infection with some of the more viru-
lent members of the relapsing fever borreliae
(B. recurrentis/B. duttonii), where mortality can
reach 10% in untreated cases.
Table 165.2 Treatment of relapsing fever borreliosis
Antibiotic Dosage used Duration Comments
Penicillin 400 000–600 000 IU daily 7 to 14 d Single dose can be curative for LBRF
CNS involvement
Tetracycline 200–250mg BID to 500mg QID 7 to 14 d Single dose can be curative for LBRF
Doxycycline 200-250mg
4mg/kg/d
7 to 14 d Can be used as prophylaxis (200mg d 1, then 100mg daily 4 d post exposure)
Erythromycin 500mg QID
(50mg/kg children)
7 to 14 d During pregnancy or children
Chloramphenicol 500mg QID
(12.5mg/kg children)
7 to 14 d During pregnancy or children
Ceftriaxone 2 g daily 7 to 14 d CNS involvement
Abbreviation: CNS ¼ central nervous system.
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LABORATORY DIAGNOSIS
Microscopy has been the primary diagnostic
approach, with demonstration of the spirochetes
in blood with Wright’s or Giemsa stains, silver
staining, or the use of dark-field microscopy for
observing motile spirochetes (Figure 165.1).
Whilst these methods can detect the causative
species, sensitivity is poor, particularly for some
species such as Borrelia crociduraewhere the blood
burden is lower than for example B. recurrentis.
This is further complicated by the need to collect
blood during febrile episodes. It is not possible to
differentiate species using microscopy.
Animal inoculation can recover and identify
cultivable strains. Cultivation can also be
achieved from clinical samples into specialized
media (such as BSKII) but this is technically
demanding. This has been largely superseded by
molecular identification approaches, and molecu-
lar diagnostics are currently the mainstay for both
detection and typing of relapsing fever borreliae.
CURRENT EPIDEMIOLOGY
The relapsing fever spirochetes have been
divided into those in the Old World and New;
however, with improving phylogenetic tools, this
division now appears artificial. The prevalence of
tick-borne strains correlates with specific regions,
particularly African TBRF, probably resulting
from climatic conditions conducive for its tick
vector. This has not been the case for louse-borne
B. recurrentis, which was formerly worldwide, but
now is restricted to areas where clothing lice
persist.
Figure 165.2 depicts the global location of
relapsing fever.
It is increasingly apparent that the burden of
relapsing fever infections in endemic regions is
underdiagnosed. Recent reports from Senegal
have suggested that this is the cause of some
13% of fevers presenting at local dispensaries,
representing an alarming 11 to 25 cases per 100
person-years. Studies of febrile patients in
Morocco have suggested that 20.5% were TBRF
cases. Although not at these levels, cases are more
frequently being detected in the USA.Figure 165.1. Motile spirochetes.
Figure 165.2. Global location of relapsing fever.
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Epidemiology of LBRF has changed drastically
with the reduced level of infestation with clothing
lice. The infection remains in areas of extreme
poverty such as Ethiopia, sometimes spilling into
adjacent regions, such as an outbreak in the
Darfur region of Sudan. During this outbreak
between 1999 and 2000 some 20 000 cases
occurred with a 10% mortality rate.
RESERVOIRS OF INFECTION
The majority of relapsing fever spirochetes are
zoonoses with vertebrate reservoir species
(Table 165.1). In the majority of cases, these reser-
voir species are rodents; however, bats, birds, and
reptiles may also have a reservoir role. The
notable exceptions are B. recurrentis and B. dutto-
nii, both of which have an exclusive human reser-
voir. Many also consider the tick vector a
reservoir of infection for TBRF, facilitated by the
impressive longevity of these ticks that can sur-
vive for many years with their infecting
spirochetes.
RISK GROUPS
Both LBRF and TBRF have their greatest burden
among those living in extreme poverty.
Occupational contact with tick-infested envir-
onments has resulted in clusters of infection, par-
ticularly among military personnel who have
used caves during training activities, with a
resulting clinical burden of up to 6.4 cases/
100 000 in Israel. Similarly, conservation workers
are at risk. Imported cases have been encountered
through migration and tourism, typically in rural
regions where intermittently used holiday accom-
modation has provided refuge for reservoir hosts
and their associated tick vectors.
CONTROL AND PREVENTION
Relapsing fever spirochetes remain susceptible to
penicillin, tetracycline/doxycycline, chloram-
phenicol, ceftriaxone, and erythromycin
(Table 165.2). Wide use of antimicrobials coupled
with improvements in living conditions has
reduced the incidence of infection. This is not so
apparent for the tick-borne forms of disease that
persist in their longer-lived tick vector/reservoirs
and through zoonotic vertebrate reservoir
species. The burden of TBRF among subsistence
agro-pastoralist communities in developing
nations remains substantial. Use of acaracides
has met with some success, but costs are prohibi-
tive. If contact is unavoidable, doxycycline
prophylaxis has been used for short-term
prevention.
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